Symptomatic post-bariatric hypoglycemia (PBH) is a condition that affects approximately 8% of people who have undergone bariatric surgery, characterized by exaggerated secretion of glucagon-like peptide-1 (GLP-1), dysregulated secretion of insulin, and a rapid drop in blood sugar.
Symptomatic PBH can cause severe hypoglycemic events associated with brain glucose starvation, known as neuroglycopenia, including impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability and can result in major disruptions to life, including falls, motor vehicle accidents, and job and income loss.1-6
There are no approved therapies for PBH, which affects approximately 160,000 people in the U.S.4-7 Avexitide is a first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation and highly statistically significant data and well-tolerated safety profile replicated across multiple clinical trials. Avexitide has been evaluated in five clinical trials for PBH. Amylyx expects to begin a Phase 3 program for avexitide in PBH in Q1 2025, with data readout anticipated in 2026.
At Amylyx, we are relentlessly driven by a commitment to those living with neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create more moments for the neurodegenerative community.
Our innovative approach to developing transformative therapeutics has far-reaching potential to improve the management of multiple neurodegenerative diseases. Learn more about our growing pipeline.
If you’d like to receive updates about what’s happening at Amylyx, click subscribe.